401 related articles for article (PubMed ID: 21787191)
1. Transporter-mediated drug-drug interactions.
Müller F; Fromm MF
Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
[TBL] [Abstract][Full Text] [Related]
2. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
3. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
6. Transporter-mediated Natural Product-Drug Interactions.
Bi Y; Wang X; Ding H; He F; Han L; Zhang Y
Planta Med; 2023 Feb; 89(2):119-133. PubMed ID: 35304735
[TBL] [Abstract][Full Text] [Related]
7. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
8. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
9. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
10. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.
Kindla J; Fromm MF; König J
Expert Opin Drug Metab Toxicol; 2009 May; 5(5):489-500. PubMed ID: 19416085
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
Jiang R; Dong J; Li X; Du F; Jia W; Xu F; Wang F; Yang J; Niu W; Li C
Br J Pharmacol; 2015 Feb; 172(4):1059-73. PubMed ID: 25297453
[TBL] [Abstract][Full Text] [Related]
12. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH; Leake BF; Kim RB; Ho RH
Mol Pharmacol; 2017 Jan; 91(1):14-24. PubMed ID: 27777271
[TBL] [Abstract][Full Text] [Related]
14. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
Tong Z; Yerramilli U; Surapaneni S; Kumar G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
[TBL] [Abstract][Full Text] [Related]
16. Transporter-Mediated Drug-Drug Interactions and Their Significance.
Liu X
Adv Exp Med Biol; 2019; 1141():241-291. PubMed ID: 31571167
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
19. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
20. [Role of transporters in hepatic drug disposition].
Gao CY; Chen XY; Zhong DF
Yao Xue Xue Bao; 2012 May; 47(5):565-72. PubMed ID: 22811997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]